History and Evolution of Innovations in Clinical Pharmacology Publication History and Evolution of Innovations in Clinical Pharmacology This paper reviews how decades of scientific and technological advances have transformed clinical pharmacology and…Danielle PillsburyNovember 26, 2025
Modeling amyloid plaque turnover dynamics improves characterization of drug effects Publication Modeling amyloid plaque turnover dynamics improves characterization of drug effects Researchers modeled how amyloid plaques form and clear in Alzheimer’s disease, helping explain how treatments…CertaraNovember 26, 2025
The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation Blog The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation The stepwise Paediatric Investigation Plan (PIP) is a strategic, flexible route for drug developers navigating…CertaraNovember 26, 2025
Using M&S to Evaluate Oncology Drug Dosing Blog Using M&S to Evaluate Oncology Drug Dosing Learn how modeling & simulation improves oncology drug dosing, optimizing safety, efficacy, and personalized treatment…CertaraNovember 14, 2025
ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™ Blog ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™ At ACoP 2025, Certara showcased innovation with the launch of Certara IQ™ and Phoenix® Cloud,…CertaraNovember 13, 2025
Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs Announcement Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs Certara’s new survey findings show that 50% of Americans are unaware of FDA and NIH…CertaraNovember 12, 2025
Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns On-Demand Webinar Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns Improve pediatric drug development with Certara’s Pediatric Practice, MIDD expertise for PIPs/PSPs, dose selection, regulatory…CertaraNovember 10, 2025
De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development Guide De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development Learn how Early Feasibility Assessment and QSP modeling improve drug design, de-risk feasibility studies, &…CertaraNovember 7, 2025
Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights Webinar Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights Danielle PillsburyNovember 3, 2025
Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis Publication Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis Bridge across studies with Model-based Meta Analysis, incorporating broader data & synthetic patients to enhance…CertaraOctober 31, 2025